波生坦联合西地那非治疗慢性阻塞性肺疾病合并肺动脉高压患者
Bosentan combined with sildenafil in the treatment of COPD patients with pulmonary arterial hypertension.
作者信息
Li Ying, Wang Yao, Liu Shaohua
机构信息
Department of Cardiology, Pingxiang People's Hospital Pingxiang 337000, Jiangxi Province, China.
Department of Health Management, Pingxiang People's Hospital Pingxiang 337000, Jiangxi Province, China.
出版信息
Am J Transl Res. 2021 Oct 15;13(10):11522-11530. eCollection 2021.
OBJECTIVE
To explore the impacts of bosentan combined with sildenafil on chronic obstructive pulmonary disease (COPD) patients with pulmonary arterial hypertension (PAH).
METHODS
From April 2019 to October 2020, 90 COPD patients with PAH diagnosed in our hospital were recruited and divided into groups A and B. The patients in group A (50 cases) were treated with bosentan combined with sildenafil, and the patients in group B (40 cases) were administered bosentan combined with iloprost solution for inhalation. The PAH conditions, the heart rates (HR), the cardiac function, the pulmonary function, the blood gas indexes, the inflammatory factor expressions, the incidences of adverse reactions, the overall response rates (ORR), and the patient satisfaction levels were determined or evaluated.
RESULTS
Compared with group B, the patients in group A had better recovered PAH, HR, cardiac function, pulmonary function, and blood gas indexes, lower inflammatory factor expression levels and a lower incidence of adverse reactions, as well as higher ORR and higher satisfaction levels.
CONCLUSION
Bosentan combined with sildenafil can reduce pulmonary artery pressure and promote the recovery of cardiopulmonary function in COPD patients with PAH.
目的
探讨波生坦联合西地那非对慢性阻塞性肺疾病（COPD）合并肺动脉高压（PAH）患者的影响。
方法
选取2019年4月至2020年10月在我院确诊的90例COPD合并PAH患者，分为A组和B组。A组（50例）患者接受波生坦联合西地那非治疗，B组（40例）患者接受波生坦联合吸入用伊洛前列素溶液治疗。测定或评估PAH情况、心率（HR）、心功能、肺功能、血气指标、炎症因子表达、不良反应发生率、总有效率（ORR）及患者满意度。
结果
与B组相比，A组患者的PAH、HR、心功能、肺功能及血气指标恢复更好，炎症因子表达水平更低，不良反应发生率更低，ORR更高，满意度更高。
结论
波生坦联合西地那非可降低COPD合并PAH患者的肺动脉压力，促进心肺功能恢复。
Zotero 插件